Argent Biopharma (AU:RGT) has released an update.
Argent BioPharma Ltd., a trailblazer in biopharmaceuticals, has disclosed its unaudited Preliminary Financial Report for the fiscal year ending June 30, 2024. The report, mandatory under the Australian Securities Exchange guidelines, signals the company’s continued commitment to innovative drug development, particularly in the realms of CNS and immunology. Stakeholders and potential investors can access the report online, reflecting the company’s transparent communication and growth trajectory.
For further insights into AU:RGT stock, check out TipRanks’ Stock Analysis page.
